1
Leone Bay Andrea, Moye Sherman Destardi, Wilson Bryan R: Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery. Mannkind Corporation, Leone Bay Andrea, Moye Sherman Destardi, Wilson Bryan R, sCULLMAN Louis C, March 2, 2006: WO/2006/023943 (61 worldwide citation)

Biologically active agent delivery compositions, which comprise diketopiperazine carboxylate salts are provided. Related methods for making and using the biologically active agent delivery compositions are also provided.


2
Greene Stephanie, Brandt David, Gelber Cohava, King Mark, Cheatham Wayman Wendell, Oberg Keith, Leone Bay Andrea, Hokenson Mark J, Faris Mary: Glucagon-like peptide 1(glp-1) pharmaceutical formulations. Mannkind Corporation, Greene Stephanie, Brandt David, Gelber Cohava, King Mark, Cheatham Wayman Wendell, Oberg Keith, Leone Bay Andrea, Hokenson Mark J, Faris Mary, sCULLMAN Louis C, October 25, 2007: WO/2007/121411 (56 worldwide citation)

A composition is disclosed comprising glucagon- like peptide 1 (GLP-I) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not li ...


3
Baughman Robert A, Richardson Peter, Costello Donald, Leone Bay Andrea: Delivery of active agents. Mannkind Corporation, Baughman Robert A, Richardson Peter, Costello Donald, Leone Bay Andrea, HU Yi kang, April 30, 2009: WO/2009/055742 (30 worldwide citation)

A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the ...


4
Cheatham Wayman Wendell, Leone Bay Andrea, Grant Marshall, Fog Per B, Diamond David C: Pulmonary delivery of inhibitors of phosphodiesterase type 5. Mannkind Corporation, Cheatham Wayman Wendell, Leone Bay Andrea, Grant Marshall, Fog Per B, Diamond David C, sCULLMAN Louis C, March 2, 2006: WO/2006/023944 (27 worldwide citation)

Provided herein are compositions of 1) diketopiperazine salts PDE5 inhibitors and 2) DKP microparticles having a PDE5 inhibitors thereon, as well as methods for the pulmonary delivery of these compositions for the treatment of pulmonary hypertension and sexual dysfunction(s).


5
LEONE BAY ANDREA, MOYE SHERMAN DESTARDI, WILSON BRYAN R: Microparticles comprising diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery, Mikropartikel enthaltend Diketopiperazinsalze, Diketomorpholinsalze oder Diketodioxansalze zur Arzneimitteldarreichung, Microparticules comprenant des sels de diketopiperazine, de diketomorpholine ou de dicetodioxane permettant ladministration de médicaments. MANNKIND, April 27, 2011: EP2314298-A1 (22 worldwide citation)

Microparticles comprising a pharmaceutically acceptable salt of a heterocyclic compound and a biologically active agent, wherein said microparticles release said biologically active agent, and said heterocyclic compound has the structure according to Formula 1: wherein R 1 or R 2 comprise at least o ...


6
LEONE BAY Andrea, HOUGHTEN Richard A, GUARNERI Joseph J, STOWELL Grayson W: [fr] PROCÉDÉS ET COMPOSITIONS POUR TRAITER LA DOULEUR, [en] METHODS AND COMPOSITIONS FOR TREATING PAIN. MANNKIND CORPORATION, TORREY PINES INSTITUTE FOR MOLECULAR STUDIES, CULLMAN Louis C, May 2, 2013: WO/2013/063160 (22 worldwide citation)

[en] Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administ ...


7
LEONE BAY Andrea, STOWELL Grayson W, GUARNERI Joseph J, CARLSON Dawn M, GRANT Marshall, SMUTNEY Chad C: COMPOSITION COMPRENANT UN AGONISTE DE RÉCEPTEUR DE SÉROTONINE ET UNE DICÉTOPIPÉRAZINE POUR LE TRAITEMENT DES MIGRAINES, COMPOSITION COMPRISING A SEROTONIN RECEPTOR AGONIST AND A DIKETOPIPERAZINE FOR TREATING MIGRAINES. MANNKIND CORPORATION, LEONE BAY Andrea, STOWELL Grayson W, GUARNERI Joseph J, CARLSON Dawn M, GRANT Marshall, SMUTNEY Chad C, CULLMAN Louis C, May 18, 2012: WO/2012/064892 (19 worldwide citation)

A method for treating migraines is disclosed. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent, including small molecules and peptides being administered to a patient in need of treatment. In particular, the drug delivery system is desig ...


8
FABIO Karine, GUARNERI Joseph J, CURLEY Kieran, GRANT Marshall L, LEONE BAY Andrea: [fr] COMPOSITIONS PHARMACEUTIQUES EN POUDRE SÈCHE STABLES À LA CHALEUR ET PROCÉDÉS, [en] HEAT-STABLE DRY POWDER PHARMACEUTICAL COMPOSITIONS AND METHODS. MANNKIND CORPORATION, CULLMAN Louis C, January 22, 2015: WO/2015/010092 (17 worldwide citation)

[en] Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an im ...


9
Leone Bay Andrea, Bay William Elliott, Timony Peter Edward: Process for converting organohydroxyl compounds to halides.. Stauffer Chemical Co, January 7, 1988: EP0251246-A1 (8 worldwide citation)

A process for converting organic hydroxyl-containing compounds to halides which comprises reacting the hydroxyl-containing compound with a phosphorushalide reagent of formula: RnPX5-n wherein n is selected from 1, 2 and 3; R is selected from the group consisting of C-6 to C-10 aryl and substituted a ...


10
Huang Sun Yi, Leone Bay Andrea, Schmitt Joseph Michael, Waterman Paul S: Quaternized aminomethyl acrylamide polymermicroemulsions, methods of producing and use of same.. Cytec Tech, August 17, 1994: EP0610955-A2 (6 worldwide citation)

Quaternized aminomethyl acrylamide polymer emulsions are treated by 1) adjusting the pH to about 3.6 to about 4.8, 2) adding a formaldehyde scavenger, 3) adjusting the water content of the aqueous phase to result in about 10-45 weight percent of quaternized aminomethylated acrylamide polymer and 4) ...